Semaglutide is a GLP-1 receptor agonist peptide used in research studying glucose metabolism, appetite regulation, and metabolic pathways
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease 2025 [Press release]
Semaglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Diabetes Care (2013) 36:334652
Post-Treatment Recovery : After completing conventional treatments, some patients continue IV nutrient therapy to support recovery, address accumulated deficiencies, and support overall wellness
Reconstitute one vial at a time (every 2 days) to keep solutions fresh